{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56","upperLimit":"78","value":"67"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Percentage of patients that did not have disease progression. Estimates of progression-free survival will be computed using the product-limit estimate of Kaplan and Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, and 30 and triapine IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Patients also undergo pelvic external beam radiotherapy 5 days a week during weeks 1-5. Patients may undergo parametrial boost radiation and intracavitary low-dose or high-dose rate brachytherapy as clinically indicated.\n\nPatients undergo whole-body F-18 fluorodeoxyglucose-PET/CT imaging at baseline, at 3 months after completion of study treatment, and at disease progression. Patients complete Sexual Function-Vaginal Changes Questionnaire and a smoking behavior questionnaire at baseline, at 3 months after completion of study treatment, and at disease progression.","id":"OG000","title":"Treatment (Cisplatin, Triapine, Radiation Therapy)"}],"paramType":"NUMBER","populationDescription":"Patients that completed the the 3-month 18F-FDG PET/CT.","reportingStatus":"POSTED","timeFrame":"at 18 months from study entry","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"percentage of patients"}